224 related articles for article (PubMed ID: 9493155)
21. [Intensive chemotherapy in the treatment of patients with metastatic breast cancer].
Salgado JE; Aramendía JM; Fernández-Hidalgo OA; Lozano E; Rebollo J; Martínez-Monge R; Subirá ML; Brugarolas A
Rev Med Univ Navarra; 1997; 41(3):143-51. PubMed ID: 10420919
[TBL] [Abstract][Full Text] [Related]
22. Comparison of double and triple high-dose chemotherapy with autologous blood stem cell transplantation in patients with metastatic breast cancer.
Schneeweiss A; Hensel M; Goerner R; Khbeis T; Hohaus S; Egerer G; Solomayer E; Haas R; Grischke EM; Bastert G; Ho AD
Stem Cells; 2001; 19(2):151-60. PubMed ID: 11239170
[TBL] [Abstract][Full Text] [Related]
23. Feasibility and low toxicity of early radiotherapy after high-dose chemotherapy and autologous stem cell transplantation for patients with high-risk stage II-III and locally advanced breast carcinoma.
Stemmer SM; Pfeffer MR; Rizel S; Hardan I; Goffman J; Gezin A; Neumann A; Kitsios P; Alezra D; Brenner HJ
Cancer; 2001 Jun; 91(11):1983-91. PubMed ID: 11391576
[TBL] [Abstract][Full Text] [Related]
24. High-dose chemotherapy and autologous stem cell support followed by posttransplantation doxorubicin as initial therapy for metastatic breast cancer.
deMagalhaes-Silverman M; Bloom E; Lembersky B; Lister J; Pincus S; Rybka W; Voloshin M; Wilson J; Ball E
Clin Cancer Res; 1997 Feb; 3(2):193-7. PubMed ID: 9815672
[TBL] [Abstract][Full Text] [Related]
25. A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer.
Elias AD; Richardson P; Avigan D; Ibrahim J; Joyce R; Demetri G; Levine J; Warren D; Arthur T; Reich E; Wheele C; Frei E; Ayash L
Bone Marrow Transplant; 2001 Feb; 27(3):269-78. PubMed ID: 11277174
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant treatment of high-risk stage II breast cancer with doxorubicin followed by high-dose chemotherapy and autologous stem-cell transplantation: a single-institution experience with 132 consecutive patients.
Stemmer SM; Hardan I; Raz H; Adamou AK; Inbar M; Gottfried M; Merrick Y; Cohen Y; Sulkes A; Ben-Baruch N; Pfeffer RP; Brenner HJ; Rizel S
Bone Marrow Transplant; 2003 Apr; 31(8):655-61. PubMed ID: 12692605
[TBL] [Abstract][Full Text] [Related]
27. Mobilized peripheral blood progenitor cells (PBPC) in support of tandem cycles of high-dose chemotherapy (HDC).
Meisenberg BR; Miller WE; McMillan R
Bone Marrow Transplant; 1996 Dec; 18(6):1087-93. PubMed ID: 8971377
[TBL] [Abstract][Full Text] [Related]
28. [High dosage therapy and autologous peripheral stem cell transplantation in breast carcinoma].
Kier P; Ruckser R; Buxhofer V; Habertheuer KH; Zelenka P; Tatzreiter G; Hübl G; Kittl E; Hauser A; Sebesta C; Hinterberger W
Acta Med Austriaca Suppl; 2000; 52():33-6. PubMed ID: 11261276
[TBL] [Abstract][Full Text] [Related]
29. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer.
Rodenhuis S; Bontenbal M; Beex LV; Wagstaff J; Richel DJ; Nooij MA; Voest EE; Hupperets P; van Tinteren H; Peterse HL; TenVergert EM; de Vries EG;
N Engl J Med; 2003 Jul; 349(1):7-16. PubMed ID: 12840087
[TBL] [Abstract][Full Text] [Related]
30. High-dose chemotherapy, autologous bone marrow or stem cell transplantation and post-transplant consolidation chemotherapy in patients with advanced breast cancer.
Tallman MS; Rademaker AW; Jahnke L; Brown SG; Bauman A; Mangan C; Kelly C; Rubin H; Kies MS; Shaw J; Kiel K; Gordon LI; Gradishar WJ; Winter JN
Bone Marrow Transplant; 1997 Nov; 20(9):721-9. PubMed ID: 9384473
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and toxicity of sequential high-dose therapy with peripheral blood stem cell support in patients with high-risk breast cancer.
Hohaus S; Wallwiener D; Martin S; Voso MT; Huober J; Fersis N; Bastert G; Haas R
Semin Oncol; 1998 Apr; 25(2 Suppl 4):7-11; discussion 45-8. PubMed ID: 9578056
[TBL] [Abstract][Full Text] [Related]
32. High-dose chemotherapy and stem cell transplantation for patients with stage IV breast cancer without clinically evident disease: correlation of CD34+ selection to clinical outcome.
Ahmed T; Kancherla R; Qureshi Z; Mittelman A; Seiter K; Mannancheril A; Puccio C; Chun HG; Bar M; Lipshutz M; Ali MF; Goldberg R; Preti R; Lake D; Durrani H; Farley T
Bone Marrow Transplant; 2000 May; 25(10):1041-5. PubMed ID: 10828863
[TBL] [Abstract][Full Text] [Related]
33. Phase II trial of sequential high-dose chemotherapy with paclitaxel, melphalan and cyclophosphamide, thiotepa and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer.
Vahdat LT; Balmaceda C; Papadopoulos K; Frederick D; Donovan D; Sharpe E; Kaufman E; Savage D; Tiersten A; Nichols G; Haythe J; Troxel A; Antman K; Hesdorffer CS
Bone Marrow Transplant; 2002 Aug; 30(3):149-55. PubMed ID: 12189532
[TBL] [Abstract][Full Text] [Related]
34. Myeloablative chemotherapy with autologous peripheral blood stem cell transplantation in patients with poor-prognosis solid tumors - Bulgarian experience.
Avramova B; Jordanova M; Michailov G; Konstantinov D; Christosova I; Bobev D
J BUON; 2006; 11(4):433-8. PubMed ID: 17309174
[TBL] [Abstract][Full Text] [Related]
35. High-dose cyclophosphamide, etoposide and carboplatin with autologous bone marrow support for metastatic breast cancer: long-term results.
Baker WJ; Vukelja SJ; Burrell LM; Lee N; Perry JJ
Bone Marrow Transplant; 1998 Apr; 21(8):775-8. PubMed ID: 9603400
[TBL] [Abstract][Full Text] [Related]
36. Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years.
Hanrahan EO; Broglio K; Frye D; Buzdar AU; Theriault RL; Valero V; Booser DJ; Singletary SE; Strom EA; Gajewski JL; Champlin RE; Hortobagyi GN
Cancer; 2006 Jun; 106(11):2327-36. PubMed ID: 16639731
[TBL] [Abstract][Full Text] [Related]
37. Expression of C-erbB-2/HER-2 in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous blood stem cell support.
Bewick M; Chadderton T; Conlon M; Lafrenie R; Morris D; Stewart D; Glück S
Bone Marrow Transplant; 1999 Aug; 24(4):377-84. PubMed ID: 10467326
[TBL] [Abstract][Full Text] [Related]
38. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
39. Randomized Phase II trial of two high-dose chemotherapy regimens with stem cell transplantation for the treatment of advanced ovarian cancer in first remission or chemosensitive relapse: a Southwest Oncology Group study.
Stiff PJ; Shpall EJ; Liu PY; Wilczynski SP; Callander NS; Scudder SA; Jazieh AR; Samlowski W; McCoy J; Alberts DS;
Gynecol Oncol; 2004 Jul; 94(1):98-106. PubMed ID: 15262126
[TBL] [Abstract][Full Text] [Related]
40. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J;
J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
